AstraZeneca Headquarters” height=”206″ src=”https://www.pharmaceutical-technology.com/wp-content/uploads/static-progressive/AstraZeneca-Headquarters.jpg” style=”padding: 10px” width=”300″ />
AstraZeneca has entered into a three-year collaboration agreement with healthcare information and technology provider IMS Health.
The collaboration will see both companies boost the use of real-world evidence throughout Europe in order to improve the delivery and efficacy of cost-efficient healthcare. AstraZeneca already have a similar partnership effective in the US – a data and research collaboration with WellPoint subsidiary HealthCore.
As part of the partnership, AstraZeneca will receive access to pre-existing electronic healthcare records, with patient details remaining anonymous, including clinical outcome, economic and treatment pattern data. The information will allow the company to identify unmet needs by detailing how current medicines are working in real-world settings across the European market.
AstraZeneca hopes to use the data across its discovery and clinical development programmes, with an emphasis on chronic illnesses. AstraZeneca research and development president Martin Mackay said: "This insight will help us and our healthcare decision-makers to improve the treatment of disease and ensure effective use of medicines to minimise the burden on individuals and healthcare budgets."
Caption: AstraZeneca’s headquarters, located in London, UK. Photo: AstraZeneca.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData